AU2016363591B2 - Melflufen dosage regimens for cancer - Google Patents

Melflufen dosage regimens for cancer Download PDF

Info

Publication number
AU2016363591B2
AU2016363591B2 AU2016363591A AU2016363591A AU2016363591B2 AU 2016363591 B2 AU2016363591 B2 AU 2016363591B2 AU 2016363591 A AU2016363591 A AU 2016363591A AU 2016363591 A AU2016363591 A AU 2016363591A AU 2016363591 B2 AU2016363591 B2 AU 2016363591B2
Authority
AU
Australia
Prior art keywords
melflufen
dosage
patients
administered
refractory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016363591A
Other languages
English (en)
Other versions
AU2016363591A1 (en
Inventor
Jakob LINDBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides Innovation AB
Original Assignee
Oncopeptides Innovation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016363591(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Innovation AB filed Critical Oncopeptides Innovation AB
Publication of AU2016363591A1 publication Critical patent/AU2016363591A1/en
Application granted granted Critical
Publication of AU2016363591B2 publication Critical patent/AU2016363591B2/en
Priority to AU2021200436A priority Critical patent/AU2021200436A1/en
Assigned to ONCOPEPTIDES INNOVATION AB reassignment ONCOPEPTIDES INNOVATION AB Request for Assignment Assignors: ONCOPEPTIDES AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016363591A 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer Active AU2016363591B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021200436A AU2021200436A1 (en) 2015-12-01 2021-01-22 Melflufen dosage regimens for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
GB1521217.8 2015-12-01
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200436A Division AU2021200436A1 (en) 2015-12-01 2021-01-22 Melflufen dosage regimens for cancer

Publications (2)

Publication Number Publication Date
AU2016363591A1 AU2016363591A1 (en) 2018-06-28
AU2016363591B2 true AU2016363591B2 (en) 2020-12-10

Family

ID=55177548

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016363591A Active AU2016363591B2 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer
AU2021200436A Abandoned AU2021200436A1 (en) 2015-12-01 2021-01-22 Melflufen dosage regimens for cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021200436A Abandoned AU2021200436A1 (en) 2015-12-01 2021-01-22 Melflufen dosage regimens for cancer

Country Status (27)

Country Link
US (3) US20180369141A1 (enExample)
EP (3) EP3383385B2 (enExample)
JP (2) JP6878431B2 (enExample)
KR (2) KR102279629B1 (enExample)
CN (1) CN108289876A (enExample)
AU (2) AU2016363591B2 (enExample)
BR (1) BR112018010012A8 (enExample)
CA (1) CA3003102C (enExample)
CY (1) CY1123469T1 (enExample)
DK (1) DK3383385T4 (enExample)
ES (1) ES2828033T5 (enExample)
FI (1) FI3383385T4 (enExample)
GB (1) GB201521217D0 (enExample)
HR (1) HRP20201632T4 (enExample)
HU (1) HUE051525T2 (enExample)
IL (2) IL259101A (enExample)
LT (1) LT3383385T (enExample)
MX (2) MX384724B (enExample)
PL (1) PL3383385T5 (enExample)
PT (1) PT3383385T (enExample)
RS (1) RS60986B2 (enExample)
RU (2) RU2734930C2 (enExample)
SG (1) SG11201803551YA (enExample)
SI (1) SI3383385T2 (enExample)
SM (1) SMT202000567T1 (enExample)
WO (1) WO2017093443A1 (enExample)
ZA (2) ZA201802816B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116198A1 (en) * 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
JP2022527532A (ja) 2019-04-03 2022-06-02 オンコペプティデス エービー メルフルフェンによるａｌアミロイドーシスの治療
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
WO2023281007A1 (en) * 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA2833500C (en) 2011-04-28 2019-01-08 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C PABA-PRADA, BLOOD, (2014-12-04), vol. 124, no. 21, page 2123 *
MAGAROTTO V ET AL, HAEMATOLOGICA, (2015-06-01), vol. 100, no. Suppl.1, page 89 *

Also Published As

Publication number Publication date
JP6878431B2 (ja) 2021-05-26
JP2021088560A (ja) 2021-06-10
AU2016363591A1 (en) 2018-06-28
IL301019B1 (en) 2025-08-01
US20250144023A1 (en) 2025-05-08
BR112018010012A8 (pt) 2019-02-26
LT3383385T (lt) 2020-12-28
IL301019B2 (en) 2025-12-01
MX384724B (es) 2025-03-14
KR20210092327A (ko) 2021-07-23
SI3383385T2 (sl) 2024-01-31
HRP20201632T1 (hr) 2021-01-08
RU2020134307A (ru) 2020-11-27
DK3383385T3 (da) 2020-10-12
KR20180087254A (ko) 2018-08-01
FI3383385T4 (fi) 2023-11-01
DK3383385T4 (da) 2023-11-06
PT3383385T (pt) 2020-10-26
SMT202000567T1 (it) 2020-11-10
RU2734930C2 (ru) 2020-10-26
US20220047507A1 (en) 2022-02-17
US20180369141A1 (en) 2018-12-27
BR112018010012A2 (pt) 2018-11-21
KR102279629B1 (ko) 2021-07-20
SG11201803551YA (en) 2018-05-30
MX2018006706A (es) 2018-08-01
EP3903777A1 (en) 2021-11-03
CA3003102A1 (en) 2017-06-08
MX2021008738A (es) 2021-08-24
CY1123469T1 (el) 2022-03-24
RS60986B1 (sr) 2020-11-30
ES2828033T5 (es) 2024-04-04
JP2019501881A (ja) 2019-01-24
RS60986B2 (sr) 2023-12-29
EP3383385A1 (en) 2018-10-10
ZA202102438B (en) 2025-08-27
ES2828033T3 (es) 2021-05-25
IL301019A (en) 2023-05-01
EP3383385B2 (en) 2023-09-06
NZ742548A (en) 2023-10-27
WO2017093443A1 (en) 2017-06-08
HUE051525T2 (hu) 2021-03-01
PL3383385T5 (pl) 2023-12-18
CA3003102C (en) 2022-09-13
RU2018123718A (ru) 2020-01-09
HRP20201632T4 (hr) 2023-11-10
EP3750534A1 (en) 2020-12-16
RU2018123718A3 (enExample) 2020-04-02
PL3383385T3 (pl) 2021-05-04
GB201521217D0 (en) 2016-01-13
SI3383385T1 (sl) 2020-11-30
EP3383385B1 (en) 2020-07-29
CN108289876A (zh) 2018-07-17
ZA201802816B (en) 2021-07-28
AU2021200436A1 (en) 2021-02-25
IL259101A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US20250144023A1 (en) Melflufen dosage regimens for cancer
CN111787945B (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
JP6918724B2 (ja) 急性骨髄性白血病（ａｍｌ）のための新規併用治療
JP6257734B2 (ja) デシタビン誘導体製剤
CA3013467A1 (en) Compositions containing tucaresol or its analogs
US20210401851A1 (en) Par-4 agonists for the treatment of cancer
TWI776451B (zh) Bcl-2/bcl-xl抑制劑之組合及相關用途
NZ742548B2 (en) Melflufen dosage regimens for cancer
WO2023281007A1 (en) Melflufen for use in the treatment of multiple myeloma
HK1260696A1 (en) Melflufen dosage regimens for cancer
HK1260696B (en) Melflufen dosage regimens for cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ONCOPEPTIDES INNOVATION AB

Free format text: FORMER OWNER(S): ONCOPEPTIDES AB